{
  "protocol": {
    "name": "LSD Microdosing Protocol for Mood, Creativity, and Cognitive Enhancement",
    "version": "1.0",
    "therapy_type": "lsd_microdosing",
    "condition_treated": "Subclinical Depression, Anxiety, Low Creativity, Cognitive Performance Enhancement",
    "evidence_level": "emerging_research",
    "overview": "Evidence-informed LSD microdosing protocol for mood enhancement, creativity, focus, and general well-being. Uses sub-perceptual doses (typically 5-20 micrograms) on an intermittent schedule. Based on emerging research, anecdotal reports, and harm reduction principles. Note: LSD is Schedule I in most countries; this protocol is for informational/research purposes.",
    "duration_weeks": 12,
    "total_sessions": 8,
    "evidence_sources": [
      "Fadiman J, Korb S. J Psychoactive Drugs. 2019;51(2):113-122 (PMID: 30925849)",
      "Polito V, Stevenson RJ. PLoS One. 2019;14(2):e0211023 (PMID: 30726251)",
      "Hutten NRPW, et al. J Psychopharmacol. 2019;33(9):1039-1051 (PMID: 31328653)",
      "Family N, et al. Sci Rep. 2020;10:4714 (PMID: 32170127)",
      "Szigeti B, et al. eLife. 2021;10:e62878 (PMID: 33648632)",
      "Rootman JM, et al. Sci Rep. 2021;11:14920 (PMID: 34290276)",
      "Kuypers KPC, et al. Psychopharmacology. 2019;236(2):841-851 (PMID: 30357434)"
    ]
  },
  "steps": [
    {
      "sequence_order": 1,
      "step_type": "screening",
      "title": "Initial Assessment & Goal Setting",
      "description": "Comprehensive baseline assessment to establish goals for microdosing, screen for contraindications, assess mental health status, and set realistic expectations.",
      "duration_minutes": 90,
      "required_roles": ["physician", "psychologist", "psychedelic_integration_therapist"],
      "assessment_components": {
        "mental_health_screening": [
          "Current mood and anxiety symptoms",
          "History of depression or anxiety disorders",
          "Current medications (especially psychiatric)",
          "Substance use history",
          "Personal or family history of psychosis or bipolar disorder",
          "Current life stressors and supports"
        ],
        "goals_and_intentions": [
          "What do you hope to gain from microdosing?",
          "Specific areas of improvement (mood, creativity, focus, relationships, etc.)",
          "What have you tried before?",
          "What would success look like?",
          "Realistic vs. unrealistic expectations"
        ],
        "prior_psychedelic_experience": [
          "Any prior LSD or psychedelic use?",
          "Prior microdosing experience?",
          "Response to previous psychedelics",
          "Set and setting quality in past"
        ]
      },
      "clinical_scales": [
        "PHQ-9 (depression screening)",
        "GAD-7 (anxiety screening)",
        "WHO-5 Well-Being Index",
        "Cognitive Failures Questionnaire",
        "Creativity Self-Assessment",
        "Sleep Quality Index (PSQI)"
      ],
      "education_topics": [
        "What is microdosing? (sub-perceptual doses, not 'tripping')",
        "Expected effects (subtle mood lift, enhanced focus, increased openness)",
        "Not expected effects (no hallucinations, no radical personality change)",
        "Dosing schedules (Fadiman protocol, Stamets stack, daily, etc.)",
        "Legal status and risks",
        "Importance of quality, accurate dosing (volumetric dosing)",
        "Timeline for noticing effects (days to weeks)",
        "Placebo effect considerations (may account for significant portion of effects)",
        "Harm reduction principles"
      ],
      "documentation_requirements": {
        "baseline_metrics": [
          "Mood state",
          "Anxiety level",
          "Sleep quality",
          "Productivity/focus assessment",
          "Creativity self-rating",
          "Social functioning",
          "Physical health"
        ]
      }
    },
    {
      "sequence_order": 2,
      "step_type": "screening",
      "title": "Medical & Psychological Contraindication Screening",
      "description": "Evaluate medical and psychiatric contraindications to ensure patient safety. LSD microdosing, while lower risk than full doses, still requires careful screening.",
      "duration_minutes": 60,
      "required_roles": ["physician", "psychiatrist"],
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "weight"],
        "baseline_documentation": "Establish baseline cardiovascular status"
      },
      "medical_screening": {
        "cardiovascular": [
          "History of heart disease (LSD can cause vasoconstriction, mild BP/HR elevation)",
          "Uncontrolled hypertension",
          "Arrhythmias",
          "Valvular heart disease (concern for cardiac fibrosis with chronic serotonergic drugs)"
        ],
        "neurological": [
          "Seizure disorder",
          "Migraine with aura (may be exacerbated)",
          "Other neurological conditions"
        ],
        "other": [
          "Liver or kidney disease (clearance considerations)",
          "Pregnancy or breastfeeding (contraindicated)",
          "Plans to conceive (defer microdosing)"
        ]
      },
      "psychiatric_screening": {
        "absolute_contraindications": [
          "Personal history of schizophrenia or psychotic disorder",
          "First-degree relative with schizophrenia (high genetic risk)",
          "Bipolar I disorder with manic episodes",
          "Active psychosis or delusions",
          "Severe personality disorder with poor reality testing"
        ],
        "relative_contraindications": [
          "Bipolar II disorder (proceed with extreme caution, monitor for hypomania)",
          "Severe anxiety or panic disorder (may worsen)",
          "PTSD with dissociative symptoms",
          "Obsessive-compulsive disorder (can worsen obsessions in some)",
          "Current severe depression with suicidal ideation (needs more intensive treatment)"
        ],
        "medication_interactions": [
          "SSRIs/SNRIs: Common combo, but may reduce LSD effects; no serotonin syndrome risk",
          "MAOIs: Potentially dangerous interaction, absolute contraindication",
          "Lithium: Potentially increases seizure risk, contraindicated",
          "Antipsychotics: Block LSD effects, may be taking for reason that contraindicates LSD",
          "Tramadol: Potential serotonin syndrome risk, avoid",
          "St. John's Wort: Serotonergic, use caution"
        ]
      }
    },
    {
      "sequence_order": 3,
      "step_type": "decision_point",
      "title": "Eligibility & Protocol Selection",
      "description": "Determine patient eligibility based on screening and select optimal microdosing protocol (dosing schedule, dose, duration) based on individual factors and goals.",
      "duration_minutes": 30,
      "required_roles": ["physician", "psychedelic_guide"],
      "evaluation_rules": {
        "type": "safety_and_protocol_selection",
        "eligibility_assessment": {
          "proceed": "No absolute contraindications, realistic expectations, willingness to track metrics",
          "defer": "Relative contraindication that needs optimization (e.g., unstable mood), medication adjustment needed",
          "exclude": "Absolute contraindication present (psychosis history, family schizophrenia, lithium use, MAOI use, pregnancy)"
        },
        "protocol_selection": {
          "dosing_schedules": [
            {
              "name": "Fadiman Protocol (Classic)",
              "schedule": "Day 1: Dose, Day 2: Transition (no dose), Day 3: Normal (no dose), Day 4: Dose again",
              "pattern": "Every 3 days (1 day on, 2 days off)",
              "frequency": "~2 doses per week",
              "rationale": "Allows observation of effects, transition day, and return to baseline; prevents tolerance",
              "best_for": "Beginners, those wanting clear on/off comparison, researchers tracking effects"
            },
            {
              "name": "Stamets Stack (Enhanced)",
              "schedule": "5 days on, 2 days off (weekly cycle)",
              "additional_components": "LSD + psilocybin mushroom microdose + niacin + lion's mane mushroom",
              "frequency": "5 doses per week",
              "rationale": "Paul Stamets protocol for neurogenesis and cognitive enhancement; niacin for peripheral vasodilation, lion's mane for nerve growth factor",
              "best_for": "Cognitive enhancement focus, experienced microdosers",
              "note": "This protocol combines LSD or psilocybin with other supplements"
            },
            {
              "name": "Every Other Day",
              "schedule": "Dose every other day",
              "frequency": "3-4 doses per week",
              "rationale": "More frequent dosing without daily tolerance build-up",
              "best_for": "Those who benefit from more frequent dosing, depression/anxiety management"
            },
            {
              "name": "Intuitive/As-Needed",
              "schedule": "Dose when you feel you need it (1-3 times per week)",
              "frequency": "Variable, typically 1-3 per week",
              "rationale": "Flexible approach based on individual response and needs",
              "best_for": "Experienced microdosers who know their response well",
              "caution": "Requires self-awareness to avoid overuse"
            },
            {
              "name": "Daily Microdosing",
              "schedule": "Every day for 30 days, then break",
              "frequency": "7 days per week for limited duration",
              "rationale": "Some use for short intensive period, though tolerance is a concern",
              "best_for": "Short-term intervention, not recommended long-term",
              "caution": "Risk of tolerance, receptor downregulation; take extended breaks"
            }
          ],
          "recommended_default": "Fadiman Protocol (every 3 days) for first-time microdosers"
        },
        "dose_determination": {
          "typical_range": "5-20 micrograms LSD",
          "threshold_dose": "~20-25 mcg (beginning of perceptual effects)",
          "sub_perceptual_target": "Below threshold - no obvious intoxication",
          "starting_recommendation": {
            "conservative_start": "5-8 mcg (very sensitive individuals, first-timers)",
            "standard_start": "10 mcg (most common starting dose)",
            "higher_start": "15 mcg (if experienced or less sensitive)"
          },
          "calibration_approach": "Start low, increase gradually until finding sweet spot (just below perceptual threshold)",
          "volumetric_dosing": {
            "importance": "CRITICAL - LSD doses are tiny, accurate measurement essential",
            "method": "Dissolve known amount of LSD (e.g., 100 mcg tab) in measured volume of distilled water or alcohol (e.g., 10 mL)",
            "calculation": "If 100 mcg in 10 mL, then 1 mL = 10 mcg; use oral syringe for accurate measurement",
            "storage": "Amber glass bottle, refrigerated, protected from light",
            "stability": "Stable for weeks to months if stored properly"
          },
          "signs_dose_too_high": [
            "Mild visual changes (breathing walls, color enhancement)",
            "Difficulty concentrating",
            "Feeling 'high' or altered",
            "Social awkwardness, overstimulation"
          ],
          "signs_dose_too_low": "No noticeable effects even after several weeks",
          "goal": "Subtle enhancement, not impairment - 'feeling more like yourself at your best'"
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "fadiman_protocol",
          "next_step": 4,
          "description": "Classic protocol: dose every 3 days"
        },
        {
          "outcome_id": "alternative_schedule",
          "next_step": 4,
          "description": "Every other day or other selected schedule"
        },
        {
          "outcome_id": "defer_treatment",
          "next_step": "exit_protocol",
          "description": "Contraindication or patient not ready"
        }
      ]
    },
    {
      "sequence_order": 4,
      "step_type": "preparation",
      "title": "Dose Calibration & First Microdose",
      "description": "Initial microdosing session to calibrate dose, ensure it is truly sub-perceptual, and educate on tracking and expectations. Ideally supervised or with check-in.",
      "duration_minutes": 180,
      "required_roles": ["psychedelic_guide", "physician"],
      "calibration_protocol": {
        "setting": "Comfortable, safe environment; ideally at home on a free day",
        "timing": "Morning (7-9 AM) to assess effects throughout day and avoid sleep interference",
        "preparation": [
          "Good sleep night before",
          "Healthy breakfast",
          "Clear schedule (no important commitments first calibration day)",
          "Notebook or app ready for tracking"
        ],
        "first_dose": {
          "recommended": "Start with 10 mcg (or 5 mcg if very cautious)",
          "administration": "Oral - sublingual for faster onset, or swallow",
          "volumetric_dosing": "Use prepared volumetric solution with oral syringe",
          "documentation": "Record exact dose, time, stomach contents"
        },
        "monitoring_timeline": {
          "T+30_min": "Beginning to notice anything? (Ideally no at proper microdose)",
          "T+60_min": "Any perceptual changes, mood shifts, energy changes?",
          "T+90_min": "Peak effects (if any) usually around this time",
          "T+180_min": "Assess overall effect - too much, too little, or just right?",
          "end_of_day": "Reflect on entire day - productivity, mood, social interactions, creativity",
          "next_morning": "Sleep quality, residual effects?"
        },
        "what_to_track": {
          "subjective_effects": [
            "Mood (scale 1-10)",
            "Energy level (1-10)",
            "Focus/concentration (1-10)",
            "Creativity (1-10)",
            "Anxiety level (1-10)",
            "Social ease (1-10)",
            "Any perceptual changes (yes/no, describe)",
            "Physical sensations",
            "Notable thoughts or insights"
          ],
          "objective_tracking": [
            "Productivity (tasks completed)",
            "Work quality",
            "Exercise or activity",
            "Social interactions quality",
            "Sleep hours and quality"
          ]
        }
      },
      "dose_adjustment": {
        "if_no_effects": "Increase by 2-5 mcg next dose",
        "if_subtle_positive_effects": "Stay at this dose - you found it!",
        "if_too_strong": "Decrease by 2-5 mcg next dose",
        "calibration_period": "First 2-3 doses are for finding optimal dose"
      },
      "safety_instructions": [
        "Do not drive or operate machinery if feeling ANY alteration",
        "Have a sober, trusted person you can call if needed",
        "Avoid combining with alcohol or other drugs during calibration",
        "If uncomfortable effects, remind yourself it's temporary (will pass in 6-8 hours)",
        "Stay hydrated, eat regularly"
      ]
    },
    {
      "sequence_order": 5,
      "step_type": "followup",
      "title": "Week 1 Check-In & Protocol Refinement",
      "description": "First check-in after 3-4 microdoses to review experiences, refine dose if needed, address concerns, and ensure proper tracking.",
      "duration_minutes": 45,
      "required_roles": ["psychedelic_guide", "therapist"],
      "check_in_structure": {
        "experience_review": [
          "How have the microdose days felt?",
          "Any perceptual effects? (If yes, dose likely too high)",
          "Mood, energy, focus changes noticed?",
          "Any uncomfortable effects?",
          "How about the 'off' days - any difference?",
          "Sleep quality?",
          "Any unexpected effects?"
        ],
        "tracking_review": [
          "Review patient's tracking data",
          "Are they seeing patterns?",
          "Any noticeable differences between dose days and off days?",
          "Consistency of effects or variable?"
        ],
        "dose_optimization": [
          "Current dose too high, too low, or appropriate?",
          "Make adjustments if needed",
          "Aim for subtle, barely noticeable effects - 'like a good day'"
        ],
        "protocol_adherence": [
          "Sticking to schedule?",
          "Any temptation to dose more frequently?",
          "Any challenges with the routine?"
        ],
        "expectation_management": [
          "Remind: effects are subtle, not dramatic",
          "Changes may be more noticeable in retrospect after a few weeks",
          "Placebo effect is real and that's okay - it's part of the benefit",
          "Not a magic bullet - works best with healthy lifestyle, therapy, etc."
        ]
      },
      "clinical_scales": [
        "PHQ-9 (brief version or full)",
        "GAD-7 (brief)",
        "Subjective well-being check"
      ],
      "dose_adjustments": {
        "increase_dose": "If no effects after 3-4 doses and no perceptual changes",
        "decrease_dose": "If any perceptual effects or feeling 'too stimulated'",
        "maintain_dose": "If subtle positive effects without impairment"
      }
    },
    {
      "sequence_order": 6,
      "step_type": "followup",
      "title": "Week 4 Evaluation - Early Outcomes",
      "description": "Month 1 evaluation to assess early benefits, side effects, adherence, and whether to continue protocol. Decision point for continuation.",
      "duration_minutes": 60,
      "required_roles": ["physician", "therapist"],
      "assessment_components": {
        "symptom_tracking": [
          "Compare PHQ-9, GAD-7 to baseline",
          "Mood trajectory over the month",
          "Anxiety changes",
          "Sleep quality changes",
          "Energy and motivation",
          "Cognitive function (focus, memory, creativity)",
          "Social functioning"
        ],
        "subjective_assessment": [
          "Do you feel different?",
          "What's better? What's the same or worse?",
          "Quality of life changes?",
          "Productivity or creativity shifts?",
          "Relationships improved?",
          "Overall: is it helping?"
        ],
        "tracking_data_review": [
          "Review 4 weeks of daily tracking",
          "Dose days vs. off days patterns",
          "Consistency of effects",
          "Unexpected findings"
        ],
        "side_effects": [
          "Any negative effects?",
          "Insomnia or sleep disruption?",
          "Anxiety or agitation?",
          "Physical discomfort?",
          "Interpersonal issues?",
          "Cognitive impairment or distractibility?"
        ],
        "adherence": [
          "How well did you stick to the schedule?",
          "Any missed doses or extra doses?",
          "Barriers to adherence?"
        ]
      },
      "clinical_scales": [
        "PHQ-9",
        "GAD-7",
        "WHO-5 Well-Being Index",
        "Cognitive Failures Questionnaire",
        "Sleep Quality (PSQI)",
        "Creativity self-rating",
        "Patient Global Impression of Change (PGIC)"
      ],
      "outcome_categories": {
        "clear_benefit": "Measurable improvement in mood, cognition, or well-being; minimal side effects",
        "subtle_benefit": "Small improvements or subjective sense of benefit; hard to quantify",
        "unclear": "No clear pattern yet; may need more time or dose adjustment",
        "no_benefit": "No noticeable changes after 4 weeks",
        "negative_effects": "Side effects outweigh benefits"
      }
    },
    {
      "sequence_order": 7,
      "step_type": "decision_point",
      "title": "Continue, Adjust, or Discontinue Decision",
      "description": "Clinical decision based on Week 4 evaluation: continue current protocol, adjust dose/schedule, or discontinue microdosing.",
      "duration_minutes": 20,
      "required_roles": ["physician", "therapist"],
      "evaluation_rules": {
        "type": "treatment_decision",
        "decision_matrix": [
          {
            "outcome": "clear_benefit",
            "decision": "Continue current protocol for another 8 weeks (total 12 weeks), then reassess",
            "rationale": "Working well, maintain course"
          },
          {
            "outcome": "subtle_benefit_or_unclear",
            "decision": "Consider dose adjustment (increase if no perceptual effects yet) OR continue current protocol to give more time",
            "rationale": "May need more time or optimization"
          },
          {
            "outcome": "no_benefit",
            "decision": "Options: (1) Try dose increase for 2-4 more weeks, (2) Try different schedule, (3) Discontinue",
            "rationale": "Reassess whether worth continuing if no benefit"
          },
          {
            "outcome": "negative_effects",
            "decision": "Discontinue or significantly reduce dose",
            "rationale": "Risks outweigh benefits"
          }
        ],
        "dose_schedule_adjustments": {
          "if_tolerance_developing": "Switch from daily or frequent dosing to Fadiman protocol; take tolerance break (1-2 weeks off)",
          "if_effects_too_subtle": "Increase dose by 5 mcg; or increase frequency (e.g., Fadiman to every other day)",
          "if_effects_too_strong": "Decrease dose by 5 mcg; or decrease frequency",
          "if_sleep_issues": "Dose earlier in day, skip afternoon doses, or take 1-2 week break"
        },
        "tolerance_break_consideration": {
          "when": "After 4-12 weeks of consistent microdosing",
          "duration": "1-4 weeks off",
          "rationale": "Prevent tolerance, reset receptor sensitivity, assess whether benefits persist",
          "restarting": "Can resume at same dose/schedule after break"
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "continue_protocol",
          "next_step": 8,
          "description": "Continue current microdosing schedule for full 12-week trial"
        },
        {
          "outcome_id": "adjust_protocol",
          "next_step": 8,
          "description": "Modify dose or schedule, continue for 8 more weeks"
        },
        {
          "outcome_id": "discontinue",
          "next_step": "exit_protocol",
          "description": "Stop microdosing, consider alternatives"
        }
      ]
    },
    {
      "sequence_order": 8,
      "step_type": "followup",
      "title": "Week 8 Mid-Point Check-In",
      "description": "Brief check-in at 8 weeks to ensure continued safety, benefit, and adherence. Address any emerging issues.",
      "duration_minutes": 30,
      "required_roles": ["therapist", "physician"],
      "check_in_focus": [
        "How's it going overall?",
        "Sustained benefits or diminishing?",
        "Any new side effects or concerns?",
        "Adherence to protocol?",
        "Any life changes or stressors affecting response?",
        "Considering tolerance break or continuation?"
      ],
      "clinical_scales": [
        "PHQ-9 (brief)",
        "GAD-7 (brief)",
        "Well-being check"
      ],
      "safety_check": [
        "Any signs of psychological dependence? (Anxiety about missing doses, preoccupation with microdosing)",
        "Any cardiovascular symptoms?",
        "Cognitive function maintained?",
        "Sleep quality?"
      ]
    },
    {
      "sequence_order": 9,
      "step_type": "followup",
      "title": "Week 12 Final Evaluation & Long-Term Planning",
      "description": "Comprehensive end-of-protocol evaluation at 12 weeks. Assess overall outcomes, decide on long-term approach (continue, tolerance break, discontinue), and create maintenance plan.",
      "duration_minutes": 90,
      "required_roles": ["physician", "therapist", "psychedelic_integration_therapist"],
      "final_assessment": {
        "comprehensive_outcomes": [
          "Compare all metrics to baseline (PHQ-9, GAD-7, well-being, creativity, cognition, sleep)",
          "Review 12 weeks of tracking data for patterns",
          "Quantitative changes in symptoms",
          "Qualitative life improvements",
          "Areas that improved vs. unchanged",
          "Unexpected benefits or drawbacks"
        ],
        "subjective_global_assessment": [
          "Overall, was microdosing worth it?",
          "What changed in your life?",
          "What would you attribute to microdosing vs. other factors?",
          "Did it meet your initial goals?",
          "Would you recommend it to others in your situation?"
        ],
        "safety_review": [
          "Any adverse effects over 12 weeks?",
          "Cardiovascular stability?",
          "Psychological stability (no psychotic symptoms, mood destabilization)?",
          "No problematic use patterns?",
          "Cognitive function maintained or improved?"
        ]
      },
      "clinical_scales": [
        "PHQ-9",
        "GAD-7",
        "WHO-5 Well-Being Index",
        "Cognitive Failures Questionnaire",
        "PSQI (sleep quality)",
        "Creativity assessment",
        "Overall quality of life",
        "Patient Global Impression of Change (PGIC)",
        "Satisfaction with treatment"
      ],
      "long_term_planning": {
        "if_successful": {
          "options": [
            "Continue indefinitely with periodic tolerance breaks (1 week off every 4-8 weeks)",
            "Take extended tolerance break (4-8 weeks) then reassess if you want to resume",
            "Taper to less frequent schedule (e.g., weekly instead of twice weekly)",
            "Discontinue and see if benefits persist (they often do)"
          ],
          "recommended_approach": "Tolerance break of 4 weeks, then reassess. Many benefits may persist without continued dosing.",
          "monitoring": "Monthly check-ins for 3 months, then as needed"
        },
        "if_partially_successful": {
          "options": [
            "Continue with dose/schedule optimization",
            "Take tolerance break then retry",
            "Explore adjunctive approaches (therapy, meditation, lifestyle changes)",
            "Consider alternatives (psilocybin microdosing, therapeutic full doses, etc.)"
          ]
        },
        "if_unsuccessful": {
          "options": [
            "Discontinue microdosing",
            "Consider whether dosing was accurate (underdosing common issue)",
            "Explore other evidence-based treatments for your goals",
            "Consider therapeutic-dose psychedelic sessions if appropriate"
          ]
        }
      },
      "harm_reduction_recommendations": {
        "long_term_safety": [
          "Annual cardiovascular check-up (concern for valvular heart disease with chronic serotonergic agonism is theoretical but monitor)",
          "Periodic mental health screening",
          "Avoid long-term daily use (risk of tolerance, receptor changes)",
          "Take regular breaks to reset",
          "Don't increase dose over time chasing effects (tolerance sign)",
          "Quality control of source material (purity, accurate dosing)"
        ],
        "red_flags_to_discontinue": [
          "Developing tolerance (needing higher doses for same effect)",
          "Psychological dependence (anxiety without it, preoccupation)",
          "Mood destabilization (hypomania, depression worsening)",
          "Psychotic symptoms (paranoia, delusions, hallucinations outside of dosing)",
          "Cardiovascular symptoms",
          "Cognitive impairment",
          "Interpersonal problems related to use"
        ]
      }
    }
  ],
  "ongoing_monitoring": {
    "if_continuing_long_term": {
      "frequency": "Monthly check-ins first 3 months after initial protocol, then quarterly",
      "assessments": [
        "PHQ-9, GAD-7 quarterly",
        "Well-being and functioning check",
        "Safety monitoring (cardiovascular, psychological)",
        "Tolerance or dependence screening",
        "Adherence to harm reduction guidelines"
      ],
      "tolerance_breaks": {
        "recommendation": "1 week off every 4-8 weeks of continuous microdosing, or 4-8 weeks off after 12 weeks continuous",
        "purpose": "Prevent tolerance, receptor downregulation, and allow assessment of benefits without substance",
        "during_break": "Note if symptoms return or benefits persist (often persist)"
      },
      "annual_review": {
        "comprehensive_assessment": "Yearly evaluation of continued benefit, safety, and need for continuation",
        "cardiovascular_screen": "BP, HR, ECG (concern for cardiac valve issues with chronic 5-HT2B agonism is theoretical but prudent)",
        "mental_health_review": "Ensure ongoing psychological stability"
      }
    }
  },
  "safety_monitoring": {
    "absolute_contraindications": [
      "Personal history of psychotic disorder",
      "First-degree family member with schizophrenia",
      "Bipolar I disorder",
      "Current MAOI use",
      "Lithium therapy",
      "Pregnancy or breastfeeding",
      "Severe cardiovascular disease"
    ],
    "relative_contraindications": [
      "Bipolar II disorder",
      "Severe anxiety or panic disorder",
      "SSRI/SNRI use (may reduce effects)",
      "Seizure disorder",
      "Migraine with aura"
    ],
    "potential_adverse_effects": [
      {
        "effect": "Mild anxiety or overstimulation",
        "frequency": "Occasional (10-20%)",
        "management": "Reduce dose, dose earlier in day, or skip doses",
        "duration": "Hours (on dose day)"
      },
      {
        "effect": "Sleep disturbance or insomnia",
        "frequency": "Occasional (10-15%)",
        "management": "Dose earlier in day (morning only), reduce dose, or take break",
        "duration": "Night of dose day"
      },
      {
        "effect": "Headache",
        "frequency": "Occasional (5-10%)",
        "management": "Hydration, reduce dose, consider break",
        "duration": "Hours to day"
      },
      {
        "effect": "Subtle perceptual changes (dose too high)",
        "frequency": "Common if dose not calibrated (20-30%)",
        "management": "Reduce dose to truly sub-perceptual level",
        "duration": "Hours (on dose day)"
      },
      {
        "effect": "Gastrointestinal discomfort",
        "frequency": "Occasional (5-10%)",
        "management": "Take with food, reduce dose",
        "duration": "Hours"
      },
      {
        "effect": "Mood lability or irritability",
        "frequency": "Rare (1-5%)",
        "management": "Discontinue, consider whether underlying mood disorder",
        "duration": "Variable"
      },
      {
        "effect": "Increased anxiety (paradoxical)",
        "frequency": "Occasional (5-10%)",
        "management": "Reduce dose or discontinue; may not be right approach for this individual",
        "duration": "Hours to days"
      },
      {
        "effect": "Psychological dependence (feeling need to dose)",
        "frequency": "Rare with proper protocol (1-3%)",
        "management": "Tolerance break, address underlying issues, discontinue",
        "duration": "Resolves with abstinence"
      },
      {
        "effect": "HPPD (Hallucinogen Persisting Perception Disorder)",
        "frequency": "Very rare with microdosing (<1%)",
        "management": "Discontinue immediately, supportive care, usually resolves",
        "duration": "Days to months, usually self-limiting"
      }
    ],
    "signs_of_problematic_use": [
      "Dosing more frequently than protocol",
      "Increasing dose over time (tolerance chasing)",
      "Anxiety or distress on off days",
      "Preoccupation with microdosing",
      "Neglecting other self-care (exercise, therapy, sleep) in favor of microdosing",
      "Mood destabilization"
    ]
  },
  "special_populations": {
    "individuals_on_ssris_snris": {
      "considerations": [
        "Very common combination",
        "SSRIs/SNRIs may blunt LSD effects due to receptor downregulation",
        "No serotonin syndrome risk (LSD is agonist, not releaser)",
        "May need higher LSD microdose or may not respond as well",
        "Safe to combine from pharmacological standpoint",
        "Do not discontinue SSRIs to microdose without medical supervision"
      ]
    },
    "individuals_with_adhd": {
      "considerations": [
        "Anecdotal reports of benefit for focus and executive function",
        "Limited research evidence",
        "May respond differently than neurotypical individuals",
        "Consider interaction with ADHD stimulant medications",
        "Track ADHD symptoms specifically"
      ]
    },
    "individuals_with_trauma_history": {
      "considerations": [
        "LSD can bring up suppressed emotions or memories",
        "May be therapeutic if processing with therapist",
        "Can be destabilizing if not in therapy or unprepared",
        "Trauma-informed approach essential",
        "Close monitoring and integration support"
      ]
    },
    "creative_professionals": {
      "considerations": [
        "Common user group seeking creativity enhancement",
        "Evidence is mixed - some studies show benefit, others placebo",
        "May enhance divergent thinking (idea generation)",
        "May or may not enhance convergent thinking (problem-solving)",
        "Track creative output objectively (projects completed, quality ratings)"
      ]
    }
  },
  "placebo_considerations": {
    "importance": "Recent research suggests significant placebo effect in microdosing",
    "studies": [
      "Szigeti et al. (2021): Self-blinding citizen science trial found placebo accounted for much of benefit",
      "However, expectancy effects are part of therapeutic benefit - not a reason to dismiss"
    ],
    "implications": [
      "Set realistic expectations - benefits may be subtle or partially placebo",
      "Placebo response is still a real benefit if improving quality of life",
      "Combine with other evidence-based practices (therapy, lifestyle changes)",
      "Don't rely solely on microdosing as treatment for serious conditions",
      "Self-experimentation and tracking help determine individual response"
    ],
    "self_blinding_option": {
      "description": "Some individuals use self-blinding protocol (mix microdoses with placebo in identical capsules, randomize)",
      "purpose": "Control for placebo effect and discern true drug effects",
      "practicality": "Requires extra effort but increases scientific rigor of self-experiment"
    }
  },
  "legal_and_ethical_considerations": {
    "legal_status": {
      "most_countries": "LSD is Schedule I (USA) or equivalent - illegal to possess, distribute, or use",
      "exceptions": "Some jurisdictions decriminalizing or researching psychedelics",
      "risk": "Legal consequences including arrest, prosecution, criminal record",
      "medical_recommendation": "This protocol is for informational, educational, or research purposes in legal contexts only"
    },
    "sourcing_concerns": {
      "purity": "Illicit LSD purity and dosing highly variable",
      "safety": "Risk of adulterants, incorrect dosing, contamination",
      "recommendation": "If legal/research setting, obtain from legitimate research chemical supplier or pharmacy; if not, test substances and use harm reduction"
    },
    "workplace_considerations": {
      "drug_testing": "LSD generally not tested for in standard workplace drug screens, but specialized tests exist",
      "impairment": "True microdose should not cause impairment, but individual responses vary",
      "disclosure": "Consider risks/benefits of disclosing microdosing to employer"
    }
  },
  "clinical_pearls": [
    "Less is more - truly sub-perceptual dosing is the goal, not feeling 'high'",
    "Patience required - effects are subtle and may take weeks to notice",
    "Tracking is essential - without it, hard to discern patterns or benefits",
    "Placebo effect is real and significant - that's okay, it's still benefit",
    "Not a magic bullet - works best combined with therapy, lifestyle optimization, social connection",
    "Quality and accurate dosing matter - volumetric dosing is essential",
    "Tolerance breaks prevent receptor downregulation and allow reassessment",
    "Individual responses vary wildly - some people benefit greatly, others not at all",
    "Safety screening is important - psychedelics, even at low doses, are not for everyone",
    "Integration and reflection enhance benefits - journaling, therapy, mindfulness",
    "Legal risks are real - proceed with caution and awareness of jurisdiction",
    "Research is still emerging - we don't have all the answers yet"
  ]
}
